A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease
Brief description of study
The primary objective of this study is to evaluate the safety and tolerability of single and multiple doses of BIIB094 administered via intrathecal (IT) injection to participants with Parkinson's Disease (PD).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Parkinson's Disease
-
Age: Between 35 Years - 80 Years
-
Gender: All
Males and Females, Age 35-80, Diagnosed with Parkinson's Disease in the last 7 year
Updated on
19 Mar 2024.
Study ID: 849949
